Millennium Management’s Pacific Biosciences PACB Stock Holding History

Millennium Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-103,500	Closed	-$1.02M	–	6524
2023 Q4	$1.02M	Sell	103,500 -311,700	-75%	-$2.55M	﹤0.01%	4156
2023 Q3	$3.47M	Buy	415,200 +315,200	+315%	+$3.6M	﹤0.01%	3060
2023 Q2	$1.33M	Sell	100,000 -101,300	-50%	-$1.23M	﹤0.01%	3813
2023 Q1	$2.33M	Buy	201,300 +101,300	+101%	+$1.01M	﹤0.01%	3289
2022 Q4	$818K	Sell	100,000 -401,000	-80%	-$3.45M	﹤0.01%	4350
2022 Q3	$2.91M	Buy	501,000 +301,000	+151%	+$1.73M	﹤0.01%	3418
2022 Q2	$884K	Hold	200,000	–	–	﹤0.01%	4486
2022 Q1	$1.82M	Buy	200,000 +140,000	+233%	+$1.61M	﹤0.01%	3978
2021 Q4	$1.23M	Buy	+60,000	New	+$1.45M	﹤0.01%	4216
2021 Q3	–	Sell	-100,000	Closed	-$3.5M	–	7118
2021 Q2	$3.5M	Hold	100,000	–	–	﹤0.01%	3242
2021 Q1	$3.33M	Sell	100,000 -100,000	-50%	-$3.5M	﹤0.01%	3027
2020 Q4	$5.19M	Buy	+200,000	New	+$3.4M	﹤0.01%	2398

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management's PACB Position: Q2 2026 in Review

Millennium Management reduced its Pacific Biosciences (PACB) stake by 19% in Q2 2026, selling an estimated $1.35M and leaving 3,962,442 shares worth $6.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2719.

Millennium Management first reported a position in PACB in Q2 2013 and has held it in 51 quarters since. The position peaked at $38.3M in Q4 2020. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Millennium Management held 3,962,442 shares of Pacific Biosciences worth $6.66M as of Q2 2026.
Millennium Management sold 929,876 Pacific Biosciences shares in Q2 2026, an estimated $1.35M.
Pacific Biosciences made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #2719 holding.
Millennium Management first reported a position in Pacific Biosciences in Q2 2013 and has held it in 51 quarters since.
Millennium Management's Pacific Biosciences position peaked at $38.3M in Q4 2020.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.